Cost-effectiveness analysis, cost-utility analysis and influence on the budget of the Russian Federation of replacement of I generation 5TH3 receptor antagonists on palonosetron for the prevention of chemotherapy-induced nausea and vomiting


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Palonosetron is a highly effective drug for the prevention of chemotherapy-induced nausea and vomiting, but its cost is higher than the cost of the first generation 5HT3 receptors antagonists. The cost-effectiveness analysis and cost-utility analysis show that «cost-effectiveness» indicator is 8.4-9.3 thousand rubles for an additional day without nausea and vomiting at the existing price levels. An analysis of the effect of substitution of older drugs for palonosetron on the budget of the Russian Federation showed that the increase in expenses depends on the frequency of its use for prevention and ranges from 35 to 489 million rubles per year depending on various conditions. Furthermore, palonosetron can be more effective in patients who do not respond to standard antiemetic therapy with first generation 5-HT3 receptor blockers, and with the development of delayed nausea and vomiting against the background of high- and moderately emetogenic chemotherapy. The use of palonosetron for the prevention of chemotherapy-induced nausea and vomiting leads to an increase in quality-adjusted life years by 0.51 days for a 5-day prevention cycle.

Толық мәтін

Рұқсат жабық

Авторлар туралы

S. Plavinsky

FSBEI HE “NWSMU n.a. I.I. Mechnikov"of RMH

P. Shabalkin

FSBI NMRC of Oncology n.A. N.N. Blokhin of RMH

Email: p.shabalkin@gmail.com
PhD, Secretary of the Profile Commission for the Specialty «Oncology»of RMH

Әдебиет тізімі

  1. Rojas C., Raje M., Tsukamoto T., Slusher B.S. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur. J. Pharmacol. 2014;722:26-37.
  2. Morran C., Smith D.C., Anderson D.A., McArdle C.S. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. Br. Med. J. 1979;1(6174):1323-24.
  3. Grunberg S.M., Deuson R.R., Mavros P., Geling O., Hansen M., Cruciani G., Daniele B., De Pouvourville G., Rubenstein E.B., Daugaard G. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100(10): 2261-68.
  4. Aapro M., Molassiotis A., Dicato M., Pelâez I., Rodrfguez-Lescure A., Pastorelli D., Ma L., Burke T., Gu A., Gascon P., Roila F.; PEER investigators. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann. Oncol. 2012;23(8):1986-92.
  5. Affronti M.L., Schneider S.M., Herndon J.E., Schlundt S., Friedman H.S. Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. Support Care Cancer. 2014;22(7):1897-1905.
  6. Hesketh P.J., Bohlke K., Lyman G.H., Basch E., Chesney M., Clark-Snow R.A., Danso M.A., Jordan K., Somerfield M.R., Kris M.G.; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J. Clin. Oncol. 2016;34(4):381-86
  7. Haiderali A., Menditto L., Good M., Teitelbaum A., Wegner J. Impact on daily functioning and indirect/ direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer. 2011;19(6):843-51.
  8. Viale P.H., Grande C., Moore S. Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting. Clin. J. Oncol. Nurs. 2012;16(4):E133-41.
  9. Снеговой А.В., Ларионова В.Б., Кононенко И.Б. и др. Профилактика тошноты и рвоты в онкологии. Клиническая онкогематология. 2016;1(9):75-83.
  10. Gibson S.J., Clark J.A., Chase D.M. Ovarian cancer: avoiding compromising quality of life during intense chemotherapy sessions. Expert Rev. Qual. Life Cancer Care. 2016;1(4):277-88.
  11. Celio L., Agustoni F., Testa I., Dotti K., de Braud F. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Tumori. 2012;98(3):279-86.
  12. Celio L., Denaro A., Canova S., Gevorgyan A., Bajetta E. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori. 2008;94(4):447-52.
  13. Saito M., Aogi K., Sekine I., Yoshizawa H., Yanagita Y., Sakai H., Inoue K., Kitagawa C., Ogura T., Mitsuhashi S. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10(2):115-24.
  14. Celio L., Frustaci S., Denaro A., Buonadonna A., Ardizzoia A., Piazza E., Fabi A., Capobianco A.M., Isa L., Cavanna L., Bertolini A., Bichisao E., Bajetta E. Italian Trials in Medical Oncology Group. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer. 2011;19(8): 1217-25
  15. Aapro M., Fabi A., Nole F., Medici M., Steger G., Bachmann C., Roncoroni S., Roila F. Doubleblind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann. Oncol. 2010; 21(5):1083-88.
  16. Decker G.M., DeMeyer E.S., Kisko D.L. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J. Support Oncol. 2006;4(1):35-41.
  17. Oyama K., Fushida S., Kaji M., Takeda T., Yabushita K., Nezuka H., Kinami S., Kadoya N., Takai Y., Tsukioka Y., Ohyama S., Tsuji K., Tsukada T., Kinoshita J.,Fujimura T., Ohta T. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. Int. J. Clin. Oncol. 2016;21(3):483-90.
  18. Likun Z., Xiang J., Yi B., Xin D., Tao Z.L. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist. 2011;16(2):207-16.
  19. Tricco A.C., Blondal E., Veroniki A.A., Soobiah C., Vafaei A., Ivory J., Strifler L., Cardoso R., Reynen E., Nincic V, Ashoor H., Ho J., Ng C., Johnson C., Lillie E., Antony J., Roberts D.J., Hemmelgarn B.R., Straus S.E. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. BMC Medicine. 2016;14(1):216.
  20. Sommariva S., Pongiglione B., Tarricone R. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review. Crit. Rev. Oncol. Hematol. 2016;99:13-36.
  21. Aapro M.S., Grunberg S.M., Manikhas G.M., Olivares G., Suarez T., Tjulandin S.A., Bertoli L.F., Yunus F., Morrica B., Lordick F., Macciocchi A. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol. 2006; 17(9):1441-49.
  22. Arzneiverordnungs-Report 2016: Aktuelle Daten, Kosten, Trends und Kommentare. Ed. Ulrich Schwabe, Dieter Paffrath. Berlin Heidelberg: Springer-Verlag, 2016. P 838.
  23. Tarricone R., Girolami F. Economic Evaluation of a New Antiemetic Drug - Palonosetron versus Ondansetron: Assessment of the Drug Price Ratio in Five European Countries. Clin. Drug Investig. 2005;25(9):597-608.
  24. Avritscher E.B., Shih Y.C., Sun C.C., Gralla R.J., Grunberg S.M., Xu Y., Elting L.S. Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. J. Support Oncol. 2010;8(6):242-51.
  25. Sun C.C., Bodurka D.C., Weaver C.B., Rasu R., Wolf J.K., Bevers M.W., Smith J.A., Wharton J.T., Rubenstein E.B. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005;13(4):219-27.
  26. Ягудина Р.И., Куликов А.Ю. QALY: история, методология и будущее метода. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2010;3(1):7-11.
  27. Ягудина Р.И., Куликов А.Ю., Нгуен Т. Определение «порога готовности платить» в России, в Европейских странах и в странах СНГ. Фармакоэкономика. 2011;4(1):7-12.
  28. Колбин А.С., Максимкина Е.А., Курылев А.А. Стоимость дополнительной эффективности противоопухолевых препаратов (по данным ограничительных списков). Ремедиум. 2016:11:56-60.
  29. Состояние онкологической помощи населению России в 2015 году/ Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва. МНИОИ им. П.А. Герцена - филиал ФГБУ НМИРЦ Минздрава России, 2016. С. 236.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2017

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>